Citations

Mayo Clinic

Showing 10 of 108551 citations.

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024
Wierda, William G. , Brown, Jennifer R. , Bilgrami, S, Bociek, Greg, Brander, Danielle M. , Cortese, Matthew J , Cripe, Larry D., Davis, Randall S. , Eradat, Herbert, Fakhri, Bita , Fletcher, Christopher D.�M. , Gaballa, Sameh , Hamid, Muhammad Saad , Hill, Brian T. , Kaesberg, Paul, Kamdar, Manali , Ma, Shuo , Mosse, Claudio A. , Nakhoda, Shazia , Schorr, Andrew, Seshadri, Madhav , Stephens, Deborah M. , Ujjani, Chaitra S. , Valdez, Riccardo, Wagner‐Johnston, Nina D. , Woyach, Jennifer A. , Sundar, Hema, Dwyer, Mary A., Stephens, Deborah M , Kamdar, Manali , Ma, Shuo , Fakhri, Bita , Wierda, William G. , Abramson, Jeremy S. , Awan, Farrukh T. , Kahl, Brad S. , Kipps, Thomas J. , Parikh, Sameer A. , Schuster, Stephen J. , Siddiqi, Tanya , Thompson, Meghan C

Journal of the National Comprehensive Cancer Network | April 16, 2024 | Volume: 22 | Issue: 3 | Pages: 175-204

10.6004/jnccn.2024.0018 | PMID 38626800 Get It

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are essentially different manifestations of the same disease that are similarly managed. A number of molecular and cytogenetic variables with prognostic implications have been identified. Undetectable minimal residual disease at the end of treatment with chemoimmunotherapy or venetoclax-based combination regimens is an independent predictor of improved survival among patients with previously untreated or relapsed/refractory CLL/SLL. The selection of treatment is based on the disease stage, presence or absence of del(17p) or TP53 mutation, immunoglobulin heavy chain variable region mutation status, patient age, performance status, comorbid conditions, and the agent’s toxicity profile. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with CLL/SLL.
The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals
Haimi, Ido, Sanoba, Shenin A. , Wang, Yifan , Farrell, James J. , Klute, Kelsey , Bi, Yan , Wallace, Michael B. , Kwon, Richard S. , Sussman, Daniel A. , Merchant, Nipun B. , Golan, Talia , Raitses‐Gurevich, Maria , Lowy, Andrew M. , Liau, Joy , Jeter, Joanne, Lindberg, James , Chung, Daniel C. , Earl, Julie , Brentnall, Teresa A. , Huang, Chenchan , Smerdon, Caroline , Graff, John J., Kastrinos, Fay , _, _, Wallace, Michael B , Zogopoulos, George , Everett, Jessica N. , Katona, Bryson W , Grossberg, Aaron J. , Paiella, Salvatore , Stoffel, Elena M. , Wadlow, Raymond Couric , Permuth, Jennifer B. , Jeter, Joanne , Schrader, Kasmintan A. , Kaul, Vivek , Chandarana, Hersh , Kupfer, Sonia S. , Lucas, Aimee Lee , Sears, Rosalie C. , Brand, Randall E. , Parmigiani, Giovanni , Simeone, Diane M. , _, _

Journal of the National Comprehensive Cancer Network | April 16, 2024 | Volume: 22 | Issue: 3 | Pages: 158-166

10.6004/jnccn.2023.7097 | PMID 38626807 Get It

Background: Pancreatic adenocarcinoma (PC) is a highly lethal malignancy with a survival rate of only 12%. Surveillance is recommended for high-risk individuals (HRIs), but it is not widely adopted. To address this unmet clinical need and drive early diagnosis research, we established the Pancreatic Cancer Early Detection (PRECEDE) Consortium. Methods: PRECEDE is a multi-institutional international collaboration that has undertaken an observational prospective cohort study. Individuals (aged 18–90 years) are enrolled into 1 of 7 cohorts based on family history and pathogenic germline variant (PGV) status. From April 1, 2020, to November 21, 2022, a total of 3,402 participants were enrolled in 1 of 7 study cohorts, with 1,759 (51.7%) meeting criteria for the highest-risk cohort (Cohort 1). Cohort 1 HRIs underwent germline testing and pancreas imaging by MRI/MR-cholangiopancreatography or endoscopic ultrasound. Results: A total of 1,400 participants in Cohort 1 (79.6%) had completed baseline imaging and were subclassified into 3 groups based on familial PC (FPC; n=670), a PGV and FPC (PGV+/FPC+; n=115), and a PGV with a pedigree that does not meet FPC criteria (PGV+/FPC–; n=615). One HRI was diagnosed with stage IIB PC on study entry, and 35.1% of HRIs harbored pancreatic cysts. Increasing age (odds ratio, 1.05; P <.001) and FPC group assignment (odds ratio, 1.57; P <.001; relative to PGV+/FPC–) were independent predictors of harboring a pancreatic cyst. Conclusions: PRECEDE provides infrastructure support to increase access to clinical surveillance for HRIs worldwide, while aiming to drive early PC detection advancements through longitudinal standardized clinical data, imaging, and biospecimen captures. Increased cyst prevalence in HRIs with FPC suggests that FPC may infer distinct biological processes. To enable the development of PC surveillance approaches better tailored to risk category, we recommend adoption of subclassification of HRIs into FPC, PGV+/FPC+, and PGV+/FPC– risk groups by surveillance protocols.
Hepatic CT Perfusion in Budd-Chiari Syndrome before and after Intervention
Lyu, Lulu , Xu, Peng

Radiology | April 16, 2024 | Volume: 311 | Issue: 1 | Pages: No page available

10.1148/radiol.232426 | PMID 38625011 Get It

Sequencing of Therapy Matters in the Era of Autologous Chimeric Antigen Receptor T-cell Therapy
Chohan, Karan , Nastoupil, Loretta J.

The Hematologist | April 16, 2024 | Volume: 21 | Issue: 3 | Pages: No page available

10.1182/hem.v21.3.202438 Get It

Posterolateral Acetabular Labral Repair: Drilling Using a Percutaneous Posterolateral Portal
Meta, Fabien , Rudisill, Samuel S. , Simon, Karissa N. , Krych, Aaron J. , Hevesi, Mario , Krych, Aaron J , Hevesi, Mario

Arthroscopy Techniques | April 16, 2024 | Volume: 13 | Issue: 7 | Pages: No page available

10.1016/j.eats.2024.102994 | PMID 39100270 Get It

Abstract Acetabular labral tears are commonly diagnosed in patients with hip or groin pain, most of which occur anterosuperiorly. In some cases, operative intervention in the form of arthroscopic labral repair may be necessary to restore labral function. Posterolateral tears can be technically challenging when using traditional modified anterior portal and anterolateral (AL) portal access owing to a suboptimal drill trajectory. In this article, we describe the establishment of a posterolateral (PL) portal 1 to 2 cm posterior to the tip of the greater trochanter, mirroring the distal‐to‐proximal trajectory of the AL portal and entering the capsulotomy at the 10‐o'clock position. This method highlights that the PL portal is used for drilling and anchor placement, whereas the remaining work is performed through the AL portal. This avoids the use of any shavers or burrs in the PL portal near important neurovascular structures, including the sciatic nerve. Addressing posterolateral labral tears in the 9‐ to 11‐o'clock position using a PL portal can enhance labral fixation, thereby mitigating the risk of suboptimal repairs that can negatively impact postoperative outcomes. Technique Video video See video under supplementary data.
Ischiorectal Fossa Tumors: 30-year Single-Institution Experience
Peponis, Thomas , Perry, William , Perry, William , Perry, William R , Kelley, Scott R.

Diseases of the Colon & Rectum | April 16, 2024 | Volume: 67 | Issue: 7 | Pages: 896-902

10.1097/dcr.0000000000003255 | PMID 38624099 Get It

BACKGROUND: Primary tumors of the ischiorectal fossa are rare and comprise a wide array of pathologies with varying malignant potential. Because of the low prevalence, there is a paucity of data in the literature. This article presents a case series on the management of ischiorectal fossa tumors. OBJECTIVE: To present experience from 30 years of managing ischiorectal fossa tumors. DESIGN: Retrospective single-center analysis. SETTINGS: A quaternary referral academic health care center. PATIENTS: All patients treated for ischiorectal fossa tumors were included in the study. INTERVENTIONS: All patients underwent surgical management of their disease. MAIN OUTCOME MEASURES: Disease recurrence and overall survival. RESULTS: A total of 34 patients (53% women) were identified with a median follow-up of 23 months. Twenty-one patients (62%) were diagnosed with benign and 13 (38%) with malignant tumors. All underwent surgical resection. The median tumor size was 8.4 cm. R0 resection was obtained in 28 patients. Twelve patients (35%) developed recurrence (9 after R0 resection) after a median time of 6.5 months. There were no surgical-related mortalities. LIMITATIONS: Limitations to the study include its retrospective nature, single-center experience, and small patient sample size. CONCLUSIONS: Ischiorectal fossa tumors are primarily benign; however, they are associated with high recurrence rates even in the setting of an R0 resection. Treatment should be approached in a multidisciplinary manner, preferably in centers with experience treating these tumors. Close posttreatment surveillance is imperative. See Video Abstract. TUMORES DE LA FOSA ISQUIORRECTAL: EXPERIENCIA DE 30 AÑOS EN UNA SOLA INSTITUCIÓN ANTECEDENTES: Los tumores primarios de la fosa isquiorrectal son raros y comprenden una amplia gama de patologías con potencial maligno variable. Debido a la baja prevalencia, hay escasez de datos en la literatura. Este artículo presenta una serie de casos sobre el tratamiento de los tumores de la fosa isquiorrectal. OBJETIVO: Presentar una experiencia de 30 años en el manejo de tumores de la fosa isquiorrectal. DISEÑO: Análisis retrospectivo de un solo centro. AJUSTES: Un centro de atención médica académico de referencia cuaternaria. PACIENTES: Todos los pacientes tratados por tumores de la fosa isquiorrectal. INTERVENCIONES: Todos los pacientes se sometieron a tratamiento quirúrgico de su enfermedad. PRINCIPALES MEDIDAS DE RESULTADO: Recurrencia de la enfermedad y supervivencia general. RESULTADOS: Se identificaron un total de 34 pacientes (53% mujeres) con una mediana de seguimiento de 23 meses. Veintiún pacientes (62%) fueron diagnosticados con tumores benignos y 13 (38%) con tumores malignos. Todos fueron sometidos a resección quirúrgica. El tamaño medio del tumor fue de 8,4 cm. La resección R0 se obtuvo en 28 pacientes. Doce (35%) desarrollaron recurrencia (nueve después de la resección R0) con una mediana de tiempo de 6,5 meses. No hubo mortalidades relacionadas con la cirugía. LIMITACIONES: Las limitaciones del estudio incluyen su naturaleza retrospectiva, experiencia en un solo centro y tamaño pequeño de la muestra de pacientes. CONCLUSIONES: Los tumores de la fosa isquiorrectal son principalmente benignos, sin embargo, se asocian con altas tasas de recurrencia incluso en el contexto de una resección R0. El tratamiento debe abordarse de forma multidisciplinaria y preferentemente en centros con experiencia en el tratamiento de estos tumores. Vigilancia cercana posterior al tratamiento es imperativa. (Traducción—Dr. Aurian Garcia Gonzalez)
Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD)
Zhang, Ting , Ambrodji, Alisa , Huang, Huixing, Bouchonville, Kelly J. , Etheridge, Amy S. , Schmidt, Remington E. , Bembenek, Brianna M. , Temesgen, Zoey B., Wang, Zhiquan , Innocenti, Federico , Diasio, Robert B. , Stroka, Deborah , Largiadèr, Carlo R. , Offer, Steven M. , Wang, Zhiquan

No container title available | April 16, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.94075.2 Get It

Abstract Enhancers are critical for regulating tissue-specific gene expression, and genetic variants within enhancer regions have been suggested to contribute to various cancer-related processes, including therapeutic resistance. However, the precise mechanisms remain elusive. Using a well-defined drug-gene pair, we identified an enhancer region for dihydropyrimidine dehydrogenase (DPD, DPYD gene) expression that is relevant to the metabolism of the anti-cancer drug 5-fluorouracil (5-FU). Using reporter systems, CRISPR genome edited cell models, and human liver specimens, we demonstrated in vitro and vivo that genotype status for the common germline variant (rs4294451; 27% global minor allele frequency) located within this novel enhancer controls DPYD transcription and alters resistance to 5-FU. The variant genotype increases recruitment of the transcription factor CEBPB to the enhancer and alters the level of direct interactions between the enhancer and DPYD promoter. Our data provide insight into the regulatory mechanisms controlling sensitivity and resistance to 5-FU.
Comparative analysis of patients with new onset refractory status epilepticus preceded by fever (febrile infection‐related epilepsy syndrome) versus without prior fever: An interim analysis
Jimenez, Anthony D. , Asbell, Hannah, Aydemir, Seyhmus, Basha, Maysaa , Batra, Ayush , Damien, Charlotte , Day, Gregory S. , Eka, Onome , Eschbach, Krista , Fatima, Safoora , Fields, Madeline , Haider, Hiba A. , Hantus, Stephen , Hocker, Sara E. , Aparicio, Mariel Kalkach , Kandula, Padmaja , Kang, Peter , Kim, Minjee , Marcuse, Lara , Mohamed, Wazim, Orozco, Janet, Pimentel, Cederic, Punia, Vineet , Taraschenko, Olga , Treister, Andrew , Yoo, Ji Yeoun , Zafar, Sahar F. , Zhou, Daniel J. , Zutshi, Deepti , Gaspard, Nicolas , Hanin, Aurélie , Basha, Maysaa M , Batra, Ayush , Eschbach, Krista , Gofton, Teneille E , Haider, Hiba A , Hocker, Sara, Kalkach Aparicio, Mariel , Kandula, Padmaja , Lee, Jong Woo , Mohamed, Wazim , Punia, Vineet , Steriade, Claude , Taraschenko, Olga , Yoo, Ji Yeoun , Zafar, Sahar , Zutshi, Deepti , Hirsch, Lawrence J , Hanin, Aurelie , Gaspard, Nicolas , Day, Gregory S , Kim, Minjee , Gopaul, Margaret , Foreman, Brandon , Gerard, Elizabeth E. , Gofton, Teneille , Jongeling, Amy , Kazazian, Karnig , Kellogg, Marissa , McGraw, Christopher Michael , Ramirez, Alexandra M., Steriade, Claude , Struck, Aaron F. , Hirsch, Lawrence J.

Epilepsia | April 16, 2024 | Volume: 65 | Issue: 6 | Pages: No page available

10.1111/epi.17988 | PMID 38625055 Get It

Abstract Febrile infection‐related epilepsy syndrome (FIRES) is a subset of new onset refractory status epilepticus (NORSE) that involves a febrile infection prior to the onset of the refractory status epilepticus. It is unclear whether FIRES and non‐FIRES NORSE are distinct conditions. Here, we compare 34 patients with FIRES to 30 patients with non‐FIRES NORSE for demographics, clinical features, neuroimaging, and outcomes. Because patients with FIRES were younger than patients with non‐FIRES NORSE (median = 28 vs. 48 years old, p = .048) and more likely cryptogenic (odds ratio = 6.89), we next ran a regression analysis using age or etiology as a covariate. Respiratory and gastrointestinal prodromes occurred more frequently in FIRES patients, but no difference was found for non‐infection‐related prodromes. Status epilepticus subtype, cerebrospinal fluid (CSF) and magnetic resonance imaging findings, and outcomes were similar. However, FIRES cases were more frequently cryptogenic; had higher CSF interleukin 6, CSF macrophage inflammatory protein‐1 alpha (MIP‐1a), and serum chemokine ligand 2 (CCL2) levels; and received more antiseizure medications and immunotherapy. After controlling for age or etiology, no differences were observed in presenting symptoms and signs or inflammatory biomarkers, suggesting that FIRES and non‐FIRES NORSE are very similar conditions.
Insulin Signaling Differentially Regulates the Trafficking of Insulin and Amyloid Beta Peptides at the Blood–Brain Barrier
Zhou, Andrew L. , Swaminathan, Suresh Kumar, Salian, Vrishali S. , Wang, Lushan , Curran, Geoffry L., Min, Hoon‐Ki , Lowe, Val J. , Kandimalla, Karunya K. , Min, Hoon-Ki Paul , Kandimalla, Karunya K , Salian, Vrishali

Molecular Pharmaceutics | April 16, 2024 | Volume: 21 | Issue: 5 | Pages: 2176-2186

10.1021/acs.molpharmaceut.3c00784 | PMID 38625027 Get It